FRANKLIN LAKES, N.J.,
Nov. 1, 2012 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE:BDX), a leading global
medical technology company, today announced the completion of the
sale of its BD Biosciences - Discovery Labware unit, excluding its
Advanced Bioprocessing platform, to Corning Incorporated
(NYSE:GLW), the world leader in specialty glass and ceramics.
On April 9, 2012, BD announced
that it had signed an agreement to sell these assets to
Corning.
The Company expects to record a gain within discontinued
operations in the first quarter of fiscal year 2013.
About BD
BD is a leading global medical technology company that develops,
manufactures and sells medical devices, instrument systems and
reagents. The Company is dedicated to improving people's health
throughout the world. BD is focused on improving drug
delivery, enhancing the quality and speed of diagnosing infectious
diseases and cancers, and advancing research, discovery and
production of new drugs and vaccines. BD's capabilities are
instrumental in combating many of the world's most pressing
diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs
approximately 29,000 associates in more than 50 countries
throughout the world. The Company serves healthcare institutions,
life science researchers, clinical laboratories, the pharmaceutical
industry and the general public. For more information, please visit
www.bd.com.
Contacts:
Colleen T. White, Corporate
Communications – 201-847-5369
Colleen_white@bd.com
Monique N. Dolecki, Investor
Relations – 201-847-5378
Monique_dolecki@bd.com
SOURCE BD (Becton, Dickinson and Company)